KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer

KRAS is the most frequently mutated oncogene in non‐small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy, Ádám, Pongor, Lőrinc Sándor, Szabó, András, Santarpia, Mariacarmela, Győrffy, Balázs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299512/
https://www.ncbi.nlm.nih.gov/pubmed/27859136
http://dx.doi.org/10.1002/ijc.30509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299512/
https://www.ncbi.nlm.nih.gov/pubmed/27859136
http://dx.doi.org/10.1002/ijc.30509

Ejemplares similares